

Virologic Surveillance — Percent Positive for Influenza


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories,
National Summary, October 2, 2022 – January 28, 2023

Percent Positive Fix A

Percent Positive Fix B

Percent Positive for January 28, 2023

Virologic Surveillance – Virus Characteristics



Viruses Collected in the U.S. since October 2, 2022


	Genetic Characterization		Antigenic Characterization	
Virus	Number Tested	Clade/Subclade	Number Tested	Similarity to cell-grown vaccine reference virus
A/H1	591	0.2% - 6B.1A.5a.1	79	98.7% similar
		99.8% - 6B.1A.5a.2		
А/НЗ	1,073	100% - 3C.2a1b.2a.2	158	93% similar
B/Victoria	29	13.8% - V1A.3	12	100% similar
		86.2% - V1A.3a.2		


Antiviral Susceptibility


Viruses Collected since 10/2/22


- Oseltamivir, Peramivir, Zanamivir 1,691 tested, 1 (0.2%) with reduced inhibition by oseltamivir
- Baloxavir 1,647 tested, 0 resistant

CDC









7

Summary

- Influenza activity continues to decline across the country.
- H3N2 remains the predominant virus.
- Declining activity ≠ no activity
- Surveillance continues year-round
- Upcoming meetings
 - ACIP on Feb. 22 interim VE estimates
 - WHO's Vaccine Consultation Meeting Feb. 20 24



Questions? abudd@cdc.gov

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

